Gefitinib-induced perforating dermatosis;Dermatosis perforante por gefitinib

Actas Dermo-Sifiliograficas

Volumn 97, Issue 3, 2006, Pages 208-211

  Fernández Guarino, Montse ^a   Aldanondo, Isabel ^a   González García, Carmen ^a   Garrido, Pilar ^a   Marquet, Ainhoa ^a   Pérez García, Bibiana ^a   Jaén, Pedro ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Epidermal growth receptor; Gefitinib; Perforating dermatosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB;

ADULT; ARTICLE; CASE REPORT; EMISSION TOMOGRAPHY; HUMAN; MALE; PERFORATION; SKIN BIOPSY; SKIN DISEASE; SOLID TUMOR;

EID: 33745429403     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73383-X     Document Type: Article

References (27)

1. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60:15-23.
2. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol. 2000;18:54-9.
3. Baselga J, Averbuch SD. ZD 1839 («Iressa») as an anticancer agent Drugs 2000;60:33-40.
4. Clinical Cancer Research vol. 10, 1212-18, February 2004: United States Food an Drug Administration Drug Approval Summary.
5. Mehregan AH, Coskey RJ. Perforating folliculitis. Arch Dermatol. 1968;97:394-9.
6. Patterson JW. The perforating disorders. J Am Acad Dermatol. 1984;10:561-81.
7. Mehregan AH. Transepithelial elimination. Curr Probl Dermatol. 1970;3:124-47.
8. Faver IR, Daoud MS, Su WP. Acquire reactive perforating collagenosis. Report of six cases and review of the literature. J Am Acad Dermatol. 1994;30:382-4.
9. Hudson RD, Apisaruthnarax P. Renal failure and perforating folliculitis JAMA. 1982;247:1936.
10. Hurtwitz RM. The evolution of perforating folliculitis in patients with chronic renal failure. Am J Dermatophatol. 1985;4:231-9.
11. Patterson JW, Graff GE, Eubanks RJ. Perforating folliculitis and psoriasis. J Am Acad Dermatol. 1982;7:369-76.
12. Rubio FA, Herranz P, Robauna G, Peña JM, Contreras F, Casado M. Perforating folliculitis: Report of a case in an HIV-infected men. J Am Acad Dermatol. 1999;40:300-2.
13. Carter VH, Constantine VS. Kyrlie's disease: Clinical findings in five cases and review of the literature. Arch Dermatol. 1968;97:624-32.
14. Patterson JW, Brown PC. Ultraestructural changes in acquired perforating dermatosis. Int J Dermatol. 1992;31:201-5.
15. Paulovic MD, Zecevic RD, Stamenkovic M, Stojadinovic O, Zolotarevski L. Trauma-induced perforating folliculitis. Eur J Dermatol. 2003;13:592.
16. Albanell J, Rojo F, Averuch S. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-24.
17. Hansen LA, Alexander N, Hogan ME, Sunderg JP, Dlugosz A, Theadgrill DW. Genetically null mice reveal a central role for the epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol. 1997;150:1959-75.
18. Philpott MP, Sanders D, Westgate GE, Kealey T. Effects of EFG on the morphology and patterns of DNA synthesis in isolated human hair follicules. J Invest Dermatol. 1994;102:186-91.
19. Nanney LB, Magid M, Stoschek CM, King LE. Comparison of epidermal growth factor distribution in normal human epidermis and epidermal appendages, J Invest Dermatol. 1984;83:385-93.
20. Mi-Woo L, Chul-Won S, Sang-We K. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa, an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23-6.
21. Herbst RS, Lo Russo P, Purdum M, Ward D. Dermatologic side effects associated with Gefitinib therapy: Clinical experience and management. Clin Lung Cancer. 2003;4:366-9.
22. Gee-Chen C. Paroniquia and skin hiperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:4646-51.
23. Kurokawa I, Endo K, Hirabayashi M. Purpuric drug eruption possibly due to gefitinib (correspondence). Int J Dermatol. 2005;44:167-8.
24. Van Doorm R, Kirtsching G, Shoeffer E. Follicular an epidermal alterations in patients treated with ZD 1839 (Iressa) an inhibitor of the epidermal growth factor receptor. Br J Dermatol. 2002;147:598-601.
25. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours (Correspondence). Br J Dermatol. 2004;150:238-41.
26. Forsythe B, Faulkner K. Overview of the tolerability of genfitinib (Iressa) monotherapy: Clinical experience in non-small-cell lung cancer. Drug Sat. 2004;27:1081-92.
27. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM. Practical management of patients with non-small-cell lung cancer treated with Gefitinib. J Clin Oncol. 2005;23:165-74.